Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Murdaca

Showing results (81-90 of 171) with videos related to

Pageof 18
Sort By:
Expert Opinion on Drug Safety|February 2, 2019
Update upon the infection risk in patients receiving TNF alpha inhibitorsGiuseppe Murdaca, Simone Negrini, Marco Pellecchio, et al.
Autoimmunity Reviews|July 20, 2019
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implicationsGiuseppe Murdaca, Alessandro Tonacci, Simone Negrini, et al.
Vaccines|November 27, 2021
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic ReviewFrancesca Rosamilia, Giovanni Noberasco, Dario Olobardi, et al.
International Journal of Molecular Sciences|August 16, 2019
Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal ModelsGiuseppe Murdaca, Alessandro Tonacci, Simone Negrini, et al.
Frontiers in Medicine|July 18, 2025
Editorial: Study on immune mechanism and immune intervention in connective tissue diseasesGiuseppe Murdaca, Wenru Su, Zhiming Lin, et al.
Expert Opinion on Drug Safety|April 3, 2019
Immunogenicity of infliximab and adalimumabGiuseppe Murdaca, Simone Negrini, Monica Greco, et al.
International Immunopharmacology|June 6, 2009
Two year sublingual immunotherapy affects serum leptinGiorgio Ciprandi, Mara De Amici, Mariangela Tosca, et al.
Human Immunology|November 26, 2008
Adipokines and sublingual immunotherapy: preliminary reportGiorgio Ciprandi, Mara De Amici, Giuseppe Murdaca, et al.
Clinical Immunology (Orlando, Fla.)|September 19, 2009
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitutionGiuseppe Murdaca, Paola Contini, Maurizio Setti, et al.
Expert Opinion on Drug Safety|November 13, 2015
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, et al.
Pageof 18

Showing results (81-90 of 171) with videos related to

Sort By:
Pageof 18
Expert Opinion on Drug Safety|February 2, 2019
Update upon the infection risk in patients receiving TNF alpha inhibitorsGiuseppe Murdaca, Simone Negrini, Marco Pellecchio, et al.
Autoimmunity Reviews|July 20, 2019
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implicationsGiuseppe Murdaca, Alessandro Tonacci, Simone Negrini, et al.
Vaccines|November 27, 2021
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic ReviewFrancesca Rosamilia, Giovanni Noberasco, Dario Olobardi, et al.
International Journal of Molecular Sciences|August 16, 2019
Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal ModelsGiuseppe Murdaca, Alessandro Tonacci, Simone Negrini, et al.
Frontiers in Medicine|July 18, 2025
Editorial: Study on immune mechanism and immune intervention in connective tissue diseasesGiuseppe Murdaca, Wenru Su, Zhiming Lin, et al.
Expert Opinion on Drug Safety|April 3, 2019
Immunogenicity of infliximab and adalimumabGiuseppe Murdaca, Simone Negrini, Monica Greco, et al.
International Immunopharmacology|June 6, 2009
Two year sublingual immunotherapy affects serum leptinGiorgio Ciprandi, Mara De Amici, Mariangela Tosca, et al.
Human Immunology|November 26, 2008
Adipokines and sublingual immunotherapy: preliminary reportGiorgio Ciprandi, Mara De Amici, Giuseppe Murdaca, et al.
Clinical Immunology (Orlando, Fla.)|September 19, 2009
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitutionGiuseppe Murdaca, Paola Contini, Maurizio Setti, et al.
Expert Opinion on Drug Safety|November 13, 2015
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, et al.
Pageof 18